Lupin Limited has recently informed exchanges that the company received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its injectable manufacturing facility in Nagpur, India. The report pertains to drug-device combination products.
The EIR was issued following a US FDA inspection conducted at the Nagpur site from June 10 to June 13, 2024.
Nilesh Gupta, Managing Director, Lupin, stated, “We are very pleased to have received the EIR from the US FDA for drug-device combination products at our Nagpur injectable facility. We remain committed to producing complex generic and essential products that address unmet needs.”
This EIR indicates the closure of the inspection process and reflects regulatory compliance at the Nagpur facility specific to drug-medical device combination products.
In the meantime, Lupin stock opened at 1,935.00, reaching a high of 1,961.90 and dipping to a low of 1,922.10 during the session. Over the past 52 weeks, it has peaked at 2,402.90 and hit a low of 1,493.30. As of 2:43 PM, the shares were trading 0.69% higher at Rs 1,947.50.
